Pentoxifylline and Glucose Injection Analysis Service

Pentoxifylline and Glucose Injection Analysis Service

Unlocking the Power of Analysis: Elevate Your Pentoxifylline and Glucose Injection with CD BioGlyco's Precision Service!

CD BioGlyco is an outstanding company that offers Analysis Services for Various Pharmaceuticals, such as pentoxifylline and glucose injection. We provide a comprehensive solution for clients including characterization, identification, and examination of diverse Pharmaceuticals and Biologicals. Pentoxifylline is a xanthine derivative that is commonly used as a vasodilator for inhibiting peripheral and cerebral vascular disorders. It possesses effects on dilating blood vessels, reducing blood viscosity, and improving blood flow to ischemic tissues. Our advanced technologies and experienced research team ensure accurate and reliable analysis for pentoxifylline and glucose injection, helping clients control its quality.

Fig.1 The structure of pentoxifylline. (CD BioGlyco)Fig.1 The structure of pentoxifylline. (CD BioGlyco)

Our analysis services are comprehensive and cover a wide array of facets, including but not limited:

Fig.2 Our analysis of pentoxifylline and glucose injection. (CD BioGlyco)Fig.2 Our analysis of pentoxifylline and glucose injection. (CD BioGlyco)

  • Characteristics
    The physicochemical and chemical properties of pentoxifylline and glucose injection, as well as their appearance, color, clarity, or smell, are assessed.
  • Identification
    We verify and validate the identity of an injection using various analytical techniques and methods, to ensure that it meets the requirements.
  • Content determination
    Quantitative analysis will be performed to determine the content of pentoxifylline and glucose in the injection by diverse technologies, including high-performance liquid chromatography (HPLC), gas chromatography (GS), and nuclear magnetic resonance (NMR).
  • Safety test
    Our testing service offers a variety of examinations to evaluate the quality and safety of pentoxifylline and glucose injections. Tests include checking for particles, ensuring sterility, determining microbial boundaries, and assessing levels of endotoxins. Besides, we possess various animal models to identify potential side effects, adverse reactions, and drug interactions associated with the injection to ensure safety.
  • PH value
    PH values are measured to ensure they fall within the appropriate range.
  • Relevant substances
    We also detect the presence of any impurities or related substances that may be present in the pentoxifylline and glucose Injection, including 5-hydroxymethylfurfural, a known impurity in glucose-based products.
  • Heavy metals
    We analyze to determine the levels of heavy metals present in the pentoxifylline and glucose injection, preventing potential harm to human health.
  • Osmolarity in molar concentration
    The osmolarity of the injection is analyzed to determine its concentration in terms of molar concentration, which is crucial for assessing its compatibility and stability.
  • Pharmacokinetic and pharmacodynamic analysis
    We also research the behavior of pentoxifylline and glucose injection within the body to conduct pharmacokinetic and pharmacodynamic studies.
  • Safety analysis

Publication Data

Technology: Histopathological analysis, Metabolomics

Journal: Scientific Reports

IF: 4.6

Published: 2016

Results: This study describes the development of a mouse model to mimic the concurrent condition of nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). The authors used a combination of high-fat diet-induced obesity and low-dose streptozocin-induced hyperglycemia to induce NAFLD and T2D in the mice. They then assessed the effectiveness of pentoxifylline in treating this pathological condition. The study employed various physiological assessments, pathological examinations, metabolomics studies on blood, urine, and liver, as well as measurements of gene and protein expression. Through these experiments, the researchers uncovered that pentoxifylline improved NAFLD in the hyperglycemic and dyslipidemic mice by increasing the expression of fatty acid β-oxidation. Additionally, pentoxifylline restored the glycolysis pathway and branched-chain amino acid-related pathways in these mice.


  • Our analysis service can be used to evaluate the composition and pharmacological properties of the injection to aid in drug development and formulation processes.
  • Our analysis enhances the understanding and usage of the injection in clinical practice.
  • Our analysis can be used to support ongoing research and development efforts related to pentoxifylline and glucose injection, thus contributing to the advancement of pharmaceutical innovation.


  • Our analysis service for pentoxifylline and glucose injection is comprehensive and covers various aspects, ensuring a thorough understanding of the product and its properties.
  • We are good at utilizing state-of-the-art technologies for analysis, ensuring accurate and reliable results.
  • We provide regular updates, consult on data interpretation, and offer technical support to ensure a successful outcome.

At CD BioGlyco, our pharmaceutical analysis service is designed to assist clients in ensuring the quality and safety of pharmaceutical products. With our expertise and advanced methods, we ensure that our analysis results are accurate and reliable. Contact us today to learn more about our comprehensive analysis services and how we can support your pharmaceutical development and production needs.


  1. Ye, J.H.; et al. Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. Scientific Reports. 2016, 6(1): 33102.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.